ZWZhifang Wu

Zhifang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhifang Wu has a total of 327 co-authors. Here are the top co-authors by number of shared publications:

  • Sijin Li

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, China

    32 shared publications
  • Haiyan Liu

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China

    8 shared publications
  • Hongliang Wang

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, People’s Republic of China

    8 shared publications
  • Hongliang Wang

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China

    7 shared publications
  • Jianbo Cao

    Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, China

    7 shared publications
  • Meng Liang

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China

    6 shared publications

Latest Publications

  • Self-Oxygenated Radionuclide Delivery System for Synergistic Sensitization of Tumor Chemotherapy and Radionuclide Therapy

    by Qianwen He, Menghua Yin, Min Li, Xirong Li, Yan Wang, Yingfang Song, Hongwei Qu, LeiLei Huang, Chenliang Niu, Junping Lv, et al.

    Radionuclide therapy is a clinically effective approach for precision cancer treatment. However, its efficacy is severely compromised by the hypoxic tumor microenvironment and intrinsic DNA self-repair mechanisms. Moreover, a single treatment modality is often insufficient to eradicate tumors. To address these challenges, we designed and constructed a multifunctional dendritic mesoporous silica (dendritic mesoporous silica nanoparticles)-based delivery system co-loaded with the chemotherapeutic agent 5-fluorouracil (5-FU) and catalase (CAT). The delivery system surface was modified with human serum albumin and hyaluronic acid (HA), followed by radiolabeling with the radionuclide 131I to enable tumor-targeted delivery, hypoxia alleviation, and synergistic radiotherapy−chemotherapy effects. This radionuclide delivery system exhibits excellent radiolabeling stability, biocompatibility, and SPECT imaging properties. It leverages CAT to efficiently catalyze the decomposition of endogenous H2O2 in the tumor microenvironment to generate O2, thereby significantly relieving tumor hypoxia. HA modification confers superior active tumor-targeting capability, while sustained release of 5-FU under acidic conditions at the tumor site effectively inhibits DNA replication. Both in vitro and in vivo experiments demonstrate that this system synergistically enhances the efficacy of 131I brachytherapy and 5-FU chemotherapy, leading to marked tumor growth inhibition with low systemic toxicity. Overall, this study overcomes the hypoxic tumor barrier and achieves synergistic targeted therapy combined with chemoradiotherapy, offering a novel strategy for effective and low-toxicity clinical treatment of solid tumors.

  • Open Access

    Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation

    by Xiao Han, Jun Zhang, Pingchang Guo, Junshun Chang, Bing Liu, Xin Diao, Ping Wu, Sheng He, Hua Wei, Wenjuan Dai, et al.

    Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have attracted considerable attention owing to their unexpected cardioprotective benefits in addition to glycemic control. Indeed, these inhibitors have been reported to exert anti-fibrotic effects and ameliorate NACHT, leucine-rich repeat (LRR), and pyrin domain-containing protein 3 (NLRP3)-dependent inflammation. However, whether SGLT2 inhibitors (SGLT2is) attenuate post-infarction myocardial fibrosis by suppressing NLRP3-dependent signaling remains unclear. Thus, this study aimed to investigate the mechanisms through which the SGLT2is dapagliflozin (DAPA) mitigates post-infarction myocardial fibrosis, with particular emphasis on the modulation of NLRP3-dependent signaling. Methods: Male Sprague-Dawley rats were used to establish a myocardial infarction (MI) model via left coronary artery ligation and were treated with DAPA (1 mg/kg/day). Cardiac magnetic resonance imaging was performed to evaluate cardiac function and remodeling. Serial 18F-fibroblast activation protein inhibitor-74 (18F-FAPI-74) positron emission tomography (PET) was used to track temporal changes in cardiac fibroblast (CF) activation. Myocardial fibrosis and NLRP3-dependent signaling were assessed ex vivo. The effects of DAPA on NLRP3-dependent signaling, fibroblast proliferation, phenotypic transition, and collagen synthesis were determined in vitro using cardiac fibroblasts (CFs) stimulated with lipopolysaccharide. Results: Compared with untreated MI rats, MI rats treated with DAPA exhibited significantly lower left ventricular (LV) end-systolic volume, LV end-diastolic volume, and LV mass, along with improved LV ejection fraction (57.6 ± 2.4% vs. 54.4 ± 2.1% in the MI group; p = 0.011). LV fibrosis was reduced in DAPA-treated MI rats (20.1 ± 1.9% vs. 31.1 ± 4.0% in the MI group; p = 0.0026), and fibrosis markers were significantly downregulated. In vivo 18F-FAPI-74 PET revealed that DAPA suppressed CF activation, as demonstrated by significantly reduced 18F-FAPI-74 uptake in the infarcted region. In infarcted cardiac tissue, DAPA inhibited the expression of the NLRP3 inflammasome, interleukin-1 beta (IL-1β), and interleukin-18 (IL-18). CF experiments performed in vitro showed that DAPA inhibited the nuclear factor kappa B (NF-κB)/NLRP3 pathway and attenuated CF proliferation, phenotypic transition, and collagen synthesis. Conclusions: By suppressing CF activation, DAPA improved myocardial fibrosis, adverse LV remodeling, and cardiac function post-MI, in association with inhibition of the NF-κB/NLRP3 pathway. 18F-FAPI-74 PET enabled non-invasive visualization of the anti-fibrotic effects of DAPA post-MI and may serve as a tool to monitor anti-fibrotic treatment efficacy after MI.

  • Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities

    by Yaqin Guo, Qiuyu Ji, Yang Yang, Meng Liang, Zhifang Wu

    Lecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable clinical backgrounds and similar baseline cognitive performance who underwent amyloid-β PET before and after lecanemab treatment. Quantitative analysis using Centiloid showed a greater reduction in amyloid burden in the patient who developed ARIA than in the 2 patients without ARIA. These observations suggest ARIA may be associated with more pronounced treatment-related amyloid clearance, warranting further investigation in larger cohorts.


  • Open Access

    Interpretable analysis of time-stratified survival prediction for non-small cell lung cancer patients based on FDG PET/CT radiomics

    by Caozhe Cui, Meng Liang, Yayuan Li, Xin Guan, Qiannan Wang, Mingxia Hou, Mei Ping, Yanan Zhang, Fang Hao, Jianbo Cao, et al.

  • Open Access

    Development and external validation of an explainable machine learning model for risk stratification of patients with chronotropic incompetence undergoing exercise stress SPECT-MPI: a dual-center study

    by Shuai Yang, Ruijie Ma, Weiwei Xie, Chunxia Xie, Qiting Sun, Rui Xi, Chen Wu, Meng Liang, Jianbo Cao, Sijin Li, et al.

    Background: Chronotropic incompetence is associated with increased cardiovascular risk in patients undergoing exercise stress single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI). However, prognostic tools integrating clinical, exercise, and perfusion imaging information in this population remain limited. We aimed to develop and externally validate an explainable machine-learning model for predicting major adverse cardiovascular events (MACE). Methods: This retrospective dual-center study included 1,060 patients with chronotropic incompetence (heart rate reserve < 80%) undergoing exercise stress SPECT-MPI (derivation cohort, n = 765; external validation cohort, n = 295). The primary endpoint was composite MACE. Five survival algorithms were evaluated using strict five-fold nested cross-validation. All data-dependent preprocessing, LASSO-Cox stability selection, sample-weight selection, and hyperparameter optimization were confined to the corresponding outer-training folds, and internal performance was estimated from patient-level out-of-fold (OOF) predictions. The optimal algorithm was selected using a composite score integrating discrimination and prediction-error metrics. SHapley Additive exPlanations (SHAP) analysis was used for model interpretation. Results: During a median follow-up of 63 months, 180 MACE events occurred. XGBoost achieved the highest composite score, with a nested OOF censoring-weighted C-index of 0.889 (95% CI, 0.861–0.917) and mean cumulative/dynamic AUC of 0.919 (95% CI, 0.892–0.943). Full-derivation stability selection retained five predictors: dyslipidaemia, diabetes, summed motion score, total perfusion deficit (TPD), and heart rate recovery at 3 min (HRR3). In the external cohort, the 5-year cumulative/dynamic AUC was 0.884 (95% CI, 0.818–0.933), compared with 0.834 for a Cox model using the same five predictors, 0.826 for TPD-plus-HRR3 XGBoost, and 0.811 for clinical-only XGBoost. Derivation-defined risk groups remained clearly separated for MACE in both cohorts (log-rank P < 0.001). Sensitivity analyses, including reintroduction of all six medication variables, supported the robustness of the final predictor set and model performance. Conclusions: An explainable XGBoost survival model integrating clinical, exercise, and SPECT-MPI information provided robust risk stratification in patients with chronotropic incompetence and maintained discrimination in independent external validation. The model was implemented as a web-based research calculator. Its use should remain restricted to patients meeting the study eligibility criteria, excluding those with prior myocardial infarction or coronary revascularization, pending further prospective multicenter validation. Clinical trial number: Not applicable.

  • Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization

    by Yunfan Sun, Yu Zhong, Shang Liu, Zefan Zhang, Chunqing Wang, Yang Liu, Junbing Chen, Wei Guo, Xiaoying Gu, Keqiang Rao, et al.

    The mechanisms underlying the interactions between disseminated tumor cells (DTCs) and their tissue microenvironment during metastatic colonization are currently poorly understood. We integrated multimodal single-cell and spatial profiling from liver cancer mouse models and human metastases to track the spatiotemporal dynamics of DTCs and their microenvironments from single-cell seeding to overt lung metastasis. We identified a residual population of quiescent Phgdh high DTCs that survived initial innate immune clearance and became transiently enriched in micrometastases. These cells shaped an immune-scarce microenvironment through PHGDH-dependent, H3K27me3-mediated epigenetic silencing of chemokine transcription, thereby promoting metastatic expansion. Cx3cr1 high interstitial macrophages were also transiently enriched before DTC expansion, creating an immune-privileged niche for metastatic outgrowth by recruiting immunosuppressive cells. Inactivating the PHGDH-H3K27me3 axis in DTCs or depleting interstitial macrophages restored immune surveillance and inhibited metastatic colonization. These findings provide insights into the development of micrometastasis-targeting regimens.


  • Incremental prognostic value of the hemodynamic gain index in patients undergoing exercise stress myocardial perfusion imaging

    by Shuai Yang, Ruijie Ma, Weiwei Xie, Chunxia Xie, Qiting Sun, Rui Xi, Chen Wu, Meng Liang, Jianbo Cao, Sijin Li, et al.


  • Open Access

    Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH

    by Xiaoyi Wang, Mengqi Wang, Pengzhe Han, Huanhuan Song, Xuchen Zhao, Nannan Chen, Congzhong Hu, Xueqin Liu, Xiaolong Li, Xifeng Fu, et al.

    The progression of metabolic dysfunction-associated steatohepatitis (MASH) involves complex crosstalk among hepatocellular injury, inflammation, and ductul